(IMNM) Immunome - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.365m USD | Total Return: 156% in 12m
Avg Turnover: 20.5M
Warnings
Share dilution 42.5% YoY
Altman Z'' -15.00 < 1.0 - financial distress zone
Below Avwap Earnings
Tailwinds
Leader, Confidence
Immunome, Inc. (IMNM) is a clinical-stage biotechnology firm focused on developing oncology therapeutics, primarily utilizing antibody-drug conjugate (ADC) and radioligand platforms. Its lead clinical asset, Varegacestat, is currently in Phase 3 trials for desmoid tumors, while IM-1021 is undergoing Phase 1 evaluation for solid tumors.
The company operates within the high-growth ADC sector, a class of precision medicine designed to deliver cytotoxic drugs directly to cancer cells while sparing healthy tissue. This business model requires significant research and development expenditure and relies on successful clinical trial progression to secure regulatory approval and commercial viability.
Investors should review the detailed fundamental metrics on ValueRay to better understand the companys valuation.
In addition to its clinical pipeline, Immunome is advancing preclinical candidates, including IM-3050, which targets fibroblast activation protein through radioligand therapy. The companys headquarters are located in Bothell, Washington, a prominent hub for biotechnology innovation in the United States.
- Varegacestat Phase 3 clinical trial data determines near-term path to commercial oncology revenue
- IM-1021 Phase 1 safety and efficacy results validate ADC platform development capabilities
- Research and development expenses for preclinical solid tumor pipeline impact cash runway
- Strategic partnerships and licensing agreements drive non-dilutive capital and platform validation
- FDA regulatory approval timelines for orphan drug candidates dictate future market entry
| Net Income: -224.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.33 > 0.02 and ΔFCF/TA 14.00 > 1.0 |
| NWC/Revenue: 8.17k% < 20% (prev 2.67k%; Δ 5.49k% < -1%) |
| CFO/TA -0.32 > 3% & CFO -196.5m > Net Income -224.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 21.68 > 1.5 & < 3 |
| Outstanding Shares: last quarter (113.1m) vs 12m ago 42.47% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.44% > 50% (prev 3.19%; Δ -1.75% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.91 (Total Current Assets 594.3m - Total Current Liabilities 27.4m) / Total Assets 619.8m |
| B: -1.26 (Retained Earnings -782.0m / Total Assets 619.8m) |
| C: -0.49 (EBIT TTM -236.1m / Avg Total Assets 481.2m) |
| D: -25.14 (Book Value of Equity -782.0m / Total Liabilities 31.1m) |
| Altman-Z'' = -27.81 = D |
As of May 24, 2026, the stock is trading at USD 22.96 with a total of 1,542,856 shares traded.
Over the past week, the price has changed by +3.74%,
over one month by -8.92%,
over three months by -0.64% and
over the past year by +156.03%.
Immunome has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy IMNM.
- StrongBuy: 7
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35.2 | 53.4% |
P/B = 3.8293
Revenue TTM = 6.94m USD
EBIT TTM = -236.1m USD
EBITDA TTM = -233.3m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 3.69m USD (from shortLongTermDebtTotal, last quarter) (leases 3.85m already included)
Net Debt = -579.0m USD (calculated: Debt 3.69m - CCE 582.7m)
Enterprise Value = 1.79b USD (2.36b + Debt 3.69m - CCE 582.7m)
Interest Coverage Ratio = unknown (Ebit TTM -236.1m / Interest Expense TTM 0.0)
EV/FCF = -8.69x (Enterprise Value 1.79b / FCF TTM -205.5m)
FCF Yield = -11.51% (FCF TTM -205.5m / Enterprise Value 1.79b)
FCF Margin = -2.96k% (FCF TTM -205.5m / Revenue TTM 6.94m)
Net Margin = -3.24k% (Net Income TTM -224.6m / Revenue TTM 6.94m)
Gross Margin = unknown ((Revenue TTM 6.94m - Cost of Revenue TTM 51.4m) / Revenue TTM)
Tobins Q-Ratio = 2.88 (Enterprise Value 1.79b / Total Assets 619.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 3.69m)
Taxrate = 21.0% (US default 21%)
NOPAT = -186.5m (EBIT -236.1m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 21.68 (Total Current Assets 594.3m / Total Current Liabilities 27.4m)
Debt / Equity = 0.01 (Debt 3.69m / totalStockholderEquity, last quarter 588.7m)
Debt / EBITDA = 2.48 (negative EBITDA) (Net Debt -579.0m / EBITDA -233.3m)
Debt / FCF = 2.82 (negative FCF - burning cash) (Net Debt -579.0m / FCF TTM -205.5m)
Total Stockholder Equity = 439.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -46.67% (Net Income -224.6m / Total Assets 619.8m)
RoE = -18.39% (Net Income TTM -224.6m / Total Stockholder Equity 1.22b)
RoCE = -39.86% (EBIT -236.1m / Capital Employed (Total Assets 619.8m - Current Liab 27.4m))
RoIC = -31.49% (negative operating profit) (NOPAT -186.5m / Invested Capital 592.4m)
WACC = 10.19% (E(2.36b)/V(2.37b) * Re(10.21%) + D(3.69m)/V(2.37b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 107.3%
[DCF] Fair Price = unknown (Cash Flow -205.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.90 | # QB: 1
Revenue Correlation: 38.28 | Revenue CAGR: 22.34% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.51 | Chg30d=+12.33% | Revisions=+40% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.56 | Chg30d=+8.38% | Revisions=+40% | Analysts=10
EPS current Year (2026-12-31): EPS=-2.14 | Chg30d=+9.61% | Revisions=+33% | GrowthEPS=+11.8% | GrowthRev=-63.9%
EPS next Year (2027-12-31): EPS=-2.00 | Chg30d=+5.25% | Revisions=-8% | GrowthEPS=+6.6% | GrowthRev=+3155.1%
[Analyst] Revisions Ratio: +40%